Description
Randomized phase III trial studies how well Blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Immunotherapy with Blinatumomab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than Blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
Location: SIMR (Sacramento)
Please contact Karen Everman at evermak@sutterhealth.org for study AALL1331
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
YiSheng Lee, M.D., Saunders C. Hsu, M.D
Recruitment Status
Active, Not Recruiting
Start Date
February 01, 2019